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Abstract 
Background: The clinical trials using immunotherapy have been performed for the treatment of variety of malignant 
tumors. However, large-scale meta-analysis of combined DC-CTL/CIK therapy on immune and clinical response in 
patients has not been well studied yet. The purpose of this study is to investigate the role of DC-CTL/CIK therapy and 
evaluate the changes of immune indicators and tumor serological markers both at an individual level and at a system 
level, which is an important basis for immunotherapy as well as prognosis estimation.
Methods: Three cohorts were designed to estimate therapeutic effects on patients with malignant tumors. Tumor 
serological markers were detected pre- and post-treatment by immunoradiometric methods using commercially 
available diagnostic kits. Lymphocyte subsets were identified by flow cytometry. The quality of life was assessed by 
EORTC QLQ-C30 questionnaire.
Results: In this study, we found out that Tregs was significantly reduced after transfusion of DC-CTL/CIK cells compa-
nied by decreasing serological tumor markers including AFP, CA199 and CA242 in primary liver cancer and CA724 in 
gastric cancer. A system-level analysis showed that lower percentages of Tregs were detected in patients with long-
lasting courses of immunotherapy. Strikingly, a tumor progression indicator, myeloid-derived suppressor cells (MDSC), 
was dramatically decreased in patients after DC-CTL/CIK treatment. These results suggested that DC-CTL/CIK therapy 
improves immune functions and the quality of life post-treatment versus pre-therapy, indicating that DC-CTL/CIK 
therapy might block the deterioration of invasive cancers in these patients.
Conclusions: This study demonstrated that DC-CTL/CIK therapy could reduce Tregs, MDSCs, and several crucial 
serological tumor markers in particular tumors, and improve the function of T cells immune systems and the quality of 
life in patients with malignant tumor.
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Background
Malignant tumors are refractory diseases that cause 
death and high economic burden in the world. Tradi-
tional therapeutic regimens such as surgery, radiation, 
or chemotherapy are usually accompanied  by adverse 
side-effects. Nowadays, immunotherapy has emerged 
as an effective treatment for patients with malignant 
tumors. It has been  broadly applied in clinical trials for 
the treatment of various malignant tumors. Lots of trials 
have demonstrated that the therapeutic  use of DC vac-
cines, CTL cells and  CIK  cells in the improvement of 
cancer therapy and showed promising outcomes of DC-
CTL/CIK therapy alone or combined with conventional 
therapies [1, 2]. In previous reports, several studies have 
focused on improving curative effect and evaluating the 
safety and efficacy of immunotherapy [3–8], founding 
that DC vaccines combined with CIK cells might have a 
potential to prevent tumor recurrence, increase progres-
sion-free survival rates, and improve the quality of life for 
cancer patients. Moreover, the side effects and toxicity of 
immunotherapy were mild and easily controllable.
DC-CTL/CIK treatment have displayed encouraging 
results in tumor therapy, however, several critical issues 
remain to be solved. First of all, the study of immuno-
therapy in solid tumors is still rare although several 
clinical trials had been carried out in the treatment of 
metastatic renal cell carcinoma, colorectal cancer and 
other malignancies [7, 9]. The sample sizes for most of 
trials are small. Secondly, there is still no reliable bio-
marker for evaluating clinical responses and monitor-
ing prognosis of DC-CTL/CIK therapy. The  indicators 
such as CD3, CD4, and CD8 have been selected as com-
mon indicators to assess the efficacy of immunotherapy. 
The changes of those indexes were statistically signifi-
cant in patients post-treatment versus pre-therapy, how-
ever, whether this or other biomarkers correlate with 
clinical outcome remain less explored [10–12]. Thirdly, 
there  is still no standard cell preparation system of DC-
CTL/CIK therapy. A lot of robust cell culture regimens 
have been established, however, different laboratories 
performed variously in cells culture regimens such as 
numbers of infused cells, types of additional cytokines, 
concentration and incubation time [13–16], which could 
have an impact on the efficacy of DC-CTL/CIK therapy. 
In the previous studies, Qu et al. [15] reported the num-
ber of CIK cells cultured in vitro increased to 14.3 ± 2.6 
times at 12  days culture period, and this number could 
reach to 20.5  ±  3.2 times when CIK cells was co-cul-
tured with DC cells. Pan et  al. [14] and Tao et  al. [16] 
depicted that the main functional properties of CIK 
cells might be limited by Tregs. Theoretically, improve-
ment of DC-CTL/CIK culture strategy and depletion 
of Tregs could bring  benefit  to  tumor  therapy. Thus, 
a more standardized and efficient cell production process 
is needed to be well-studied.
Therefore, in the present study, we designed three 
cohorts, totally including 83 patients, to investigate ther-
apeutic effect of DC-CTL/CIK therapy in patients with 
malignant solid tumors. To identify the essential features 
overall and investigate the therapeutic role of DC-CTL/
CIK therapy, we attempted to assess several common 
serological tumor markers and immune indicators across 
a wide range of tumor types at an individual level. And 
then, at a systematic level we performed to analyze the 
correlation between changes of Treg cells and prognosis 
and to assess the long-term quality of life. Additionally, a 
novel tumor progression indicator, myeloid-derived sup-
pressor cells (MDSC), was also being approached prelim-
inarily in this study.
Methods
Patients
We consecutively analyzed cohorts of 83 patients in three 
subgroups. The first subgroup (cohort 1) contained 60 
patients with detailed the clinicopathologic informa-
tion about sex, age, Tumor Classification, tumor-node-
metastasis (TNM) stage, adjuvant therapeutic strategies, 
serological tumor markers detection, immune indicators 
detection and follow-up of prognosis, who were from 
Biotherapy Department of Eastern Hepatobiliary Surgery 
Hospital, received DC-CTL/CIK therapy from Febru-
ary 2012 to March 2014 (25 patients with primary liver 
cancer, 10 patients with cholangiocarcinoma, 11 patients 
with lung cancer, 7 patients with gastric cancer and 7 
patients with colon cancer). In Cohort 2, 14 patients with 
negative for all serological tumor indexes were reviewed. 
Cohort 3 included nine patients for MDSC detection. 
The peripheral blood samples were accessed in Depart-
ment of Biotherapy, Eastern Hepatobiliary Surgery Hos-
pital, the Second Military Medical University (China). All 
patients signed informed consents.
DC‑CTL/CIK cells culture regimen
Peripheral blood mononuclear cells (PBMCs) were har-
vested by blood cell separator (FreseniusKabi, Germany). 
About 1 × 109–3 × 109 PBMC cells/40–60 ml white cells 
were collected from each patient, and were cultured in 
AIM-V cell culture solution (Gibco, America) for 2 h. The 
adherent cells were initiated into culture for DC matura-
tion by 100  ng/ml GM-CSF (PeproTech, America) and 
100 ng/ml IL-4 (PeproTech, America) in AIM-V cell cul-
ture solution. Part of the non-adherent cells were stored 
at −80  °C and thawed for co-cultivation, and the rest 
were applied for inducing CIKs.
On Day 6, the recombinant non-proliferative adeno-
virus (serotype 35) carrying the expression cassettes of 
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tumor-associated antigens (TAAs) were used to infect the 
DC cells with a multiplicity of infection (MOI) of 5. After 
24  h cultivation, IL-1β (25  ng/ml; Novoprotein, China) 
and TNF-α (100 ng/ml; Novoprotein, China) were added 
into the culture for DC-maturation for another 24 h.
On day 8, about 2  ×  106 DC  cells  were  har-
vested and co-cultured with T cells (about 4 × 107 cells) 
at a DC/T cell ratio of 1:20 for another 4 days to induce 
antigen-specific CTL cells which were stimulated with 
CD3  monoclonal antibody (mAb) (50  ng/ml; Novopro-
tein, China)  pre-coated onto plastic plates and ampli-
fied  by  IL-2 (500  IU/ml; Novoprotein, China). The rest 
cells were applied as DC vaccine. The applied TAAs 
included p53, survivin, hTERT and additional AFP/CEA 
for AFP/CEA positive patients.
Additionally, CIKs were cultured in 4 × 40 Ml serum-free 
medium supplemented with 1000 U/mL IL-2, 5 μg/mL CD3 
monoclonal antibodies, 12.5 μg/ml RetroNectin (Novopro-
tein, China) and 1000 U/mL IFN-γ (Novoprotein, China).
Cell collection and centrifugation
Cells  were harvested on day 8, transferred from 
medium bags into centrifuge bottles, and  centri-
fuged  at  1500  rpm  for  5  min, removed the supernatant 
by aspiration, washed twice by adding normal saline, then 
removed the supernatant and re-suspended the cell pellet 
in 300 ml normal saline and 500 μl IL-2. We transferred 
cells into transfer bag, heated seal the bag and prepared 
for clinical infusions. The protocol of cell collection and 
centrifugation on day 10 and day 12 is the same as day 8.
Preparation for infusions
The infused cells were cultured for detecting levels of 
bacteria, fungus and endotoxin by using BacT/ALERT® 
3D instrument (Biomerieux, America) and and PREVI® 
Color Gram (Biomerieux, America).
In total, the final volume is 1200  ml (300  ml/per 
bag ×  4 bag =  1200  ml). Promethazine  is used  to treat 
allergy  symptoms 10  min before  starting the treatment. 
The usual dose is 12.5  mg by intramuscular injection. 
After the infusion, Sodium bicarbonate  is used to make 
the  urine  more  alkaline to prevent kidney failure. Dur-
ing the procedure of infusion, the drop speed in the first 
15 min is 30 drops/min. If patients have no adverse reac-
tion after 15 min, we adjust the drop speed at 80 drops/
min.
Treatment schedules
For each treatment, patients were treated with 3 intrave-
nous infusions. About 1 × 107 DC vaccine, 1 × 109 CIKs 
and both DC vaccine and CTLs (about 1  ×  109 cells) 
were infused intravenously on day 8, day 10 and day 12 
respectively.
Detection of immune indicators by flow cytometry
The immune phenotypes and cytokine  production were 
identified by FC500 flow cytometer (Beckman Coulter, 
USA) and Guava  easyCyte™ flow cytometers (Merck 
Millipore, Germany). The monoclone antibodies were 
CD3+ to evaluate total T lymphocytes, CD3+/CD4+ to 
evaluate Helper  T cells, CD3+/CD8+ to evaluate cyto-
toxic T cells (CTLs), CD3+/CD56+ to evaluate cytokine-
induced killer (CIKs), CD4+/CD25+/CD127low/− to 
evaluate regulatory  T  cells (Tregs), CD80/CD86/CD83/
CD11c to evaluate Dendritic cells (DCs), IFN-r to eval-
uate production of Interferon gamma and CD11b+/
CD33+/HLA−DR− to evaluate Myeloid-derived sup-
pressor cells (MDSCs) [17]. The proportion of Treg cells 
was calculated by the ratio of CD25hiCD127lo/− cells to 
CD4+ cells. The proportion of MDSC cells was calcu-
lated by the ratio of CD11b+ CD33+ cells to HLADR− 
cells. The flow cytometry data were analyzed by CXP 
software and guavaSoft™ 3.1.1.
Detection of serological tumor markers 
by immunoradiometric methods
Serum AFP (Autobio, China), CEA (Roche, Switzerland), 
CA19-9 (Bayer, America), CA125 (Roche, Switzerland), 
CA242 (DPC, America) and CA724 (DPC, America) 
were detected by immunoradiometric methods with 
commercially available diagnostic kits, respectively. The 
recommended cutoff-values for diagnostic purpose were 
20  μg/L for AFP, 5  μg/L for CEA, 37 U/ml for CA19-9, 
35 U/ml for CA125, 12 U/ml for CA242 and 6 U/ml for 
CA742. Values above the cutoff concentrations were con-
sidered positive in this study.
Evaluation and statistical analysis
Statistical analyses were completed using statistical SPSS 
22 software (SPSS, Chicago, IL, USA). Analysis of bio-
markers was measured using paired t test with P < 0.05 
considered significant. The EORTC QLQ-C30 question-
naire [18, 19], developed by European Organization for 
Research and Treatment of Cancer (EORTC), is used 
to assess the quality of life of cancer patients. The  haz-
ard  ratio was calculated by Cox’s proportional hazards 
regression method.
Side effects
The criteria used to assess side effects included tempera-




We included patients with malignant tumors are not 
cured by traditional forms of therapeutic regimens 
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such as surgery, radiation, or chemotherapy. The demo-
graphic characteristics of patients enrolled were  shown 
in Table  1.  Our analysis mainly  used the data of cohort 
1, in which 60 patients with high  preoperative  levels  of 
the  serum tumor markers have received  at  least  two 
cycles of DC-CTL/CIK therapy. Fifty-nine patients with 
enough peripheral blood were available for analysis by 
flow cytometry, while one case was excluded for missing 
data. Median age of the patient was 54 years with a range 
of 27–81  years, 18 were female and 42 were male. The 
pathologic stage was Stage I in 3 patients (5 %), Stage II in 
4 patients (6.7 %), Stage IIIA in 12 patients (20 %), Stage 
IIIB in 2 patient (3.3 %), Stage IIIC in 9 patient (15 %) and 
Stage IV in 27  patients  (45  %).  Among the 60 patients, 
48 % (29/60) of the patients have received surgery before, 
and 40 % (24/60) of the patients received other adjuvant 
therapeutic strategies during the immunotherapy in 
which 18 (30 %) cases received chemotherapy, 8 (13.3 %) 
cases received radiation therapy, 2 (3.3 %) cases received 
physiotherapy and molecular targeted therapy, respec-
tively, and other 9 (15  %) cases received interventional 
treatment. The detail information of cohort 2 and cohort 
3 was also listed in Table  1. Furthermore, we subse-
quently performed univariate analyses by using the Cox 
proportional hazards regression model. Table  2 showed 
that there were no statistically significant differences 
between the two groups in terms of variables such as sex, 
age, TNM stage and receipt of adjuvant therapeutic strat-
egies or not (P > 0.05), which ensured that our statistical 
analysis of immunotherapy efficacy was comparable.
Quality control and phenotypes of infused cells
DCs immunophenotype changes were detected by flow 
cytometry at Day 8. As show in Fig. 1a, it exhibited high-
level expression of CD11c (98.71 ± 0.93 %), costimulatory 
molecules CD80 (86.55 ± 4.36 %), CD86 (95.11 ± 6.13 %) 
as well as the maturation marker CD83 (83.65 ± 1.12 %), 
which confirmed the maturation of DC cells after culti-
vation. Remarkably, the proportion of CD3+ CD56+ 
cells in vitro incubation reached 24.97 ± 3.13 % at Day 10. 
The percentage of cytotoxic T-lymphocytes (CTL, CD3+ 
CD8+) at day 12 reached 88.19 ± 1.43 %. The plot of flow 
cytometry was also shown in Figs.  1b and 2a. Notably, 
IFN-γ exhibited high production during in vitro cultiva-
tion, and the proportion of T cells expressing IFN-γ was 
determined to be 18.6  % on Day 12, compared to Ad-
blank group (Fig. 2b). Additionally, the infused cells were 
cultured for the detection of bacteria, fungus and endo-
toxin levels, all of which met the release criteria.
Individual analysis of the changes of immune indicators 
and serological tumor markers pre‑ and post‑treatment
We firstly observed the changes of serological tumor 
markers and immune indicators pre-therapy and post-
treatment (defined as  their most recent  course of 
Table 1 Characteristics of patients
Characteristic Cohort 1 N (%) Cohort 2 N (%) Cohort 3 N (%)
No. of patients, N 60 14 9
Sex
 Male 42 (70 %) 8 (57.1 %) 6 (66.7 %)
 Female 18 (30 %) 6 (42.9 %) 3 (33.3 %)
Age, median years 
(range)




10 (16.7 %) 0 2 (22.2 %)
 Colon cancer 7 (11.7 %) 1 (7.1 %) 0
 Gastric cancer 7 (11.7 %) 0 0
 Lung cancer 11 (18.3 %) 4 (28.6 %) 2 (22.2 %)
 Primary liver 
cancer
25 (41.7 %) 1 (7.1 %) 2 (22.2 %)
 Other 0 8 (57.1 %) 3 (33.3 %)
TNM staging
 Stage I 3 (5 %) 1 (7.1 %) 2 (22.2 %)
 Stage II 4 (6.7 %) 0 1 (11.1 %)
 Stage IIIA 12 (20 %) 2 (14.3 %) 1 (11.1 %)
 Stage IIIB 2 (3.3 %) 0 0
 Stage IIIC 9 (15 %) 4 (28.6 %) 1 (11.1 %)
 Stage IV 27 (45 %) 6 (42.9 %) 3 (33.3 %)
 Missing data 3 (5 %) 1 (7.1 %) 1 (11.1 %)
Adjuvant therapeutic strategies
 Without 24 (40 %) 5 (35.7 %) 7 (77.8 %)
 With 36 (60 %) 9 (64.3 %) 2 (22.2 %)
 Chemotherapy 18 (30 %) 6 (42.9 %) 1 (11.1 %)
 Radiation therapy 8 (13.3 %) 1 (7.1 %) 1 (11.1 %)
 Physiotherapy 2 (3.3 %) 0 1 (11.1 %)
 Interventional 
treatment
9 (15 %) 2 (14.3 %) 0
 Molecular tar-
geted therapy
2 (3.3 %) 1 (7.1 %) 0
Table 2 Univariate analysis in patients
CI confidence interval
Variables OR (95 % Cl) P
Sex (male vs. female) 0.880 (0.360–2.153) 0.779
Age (≤54 vs. >54) 1.003 (0.411–2.447) 0.995
TNM stage (I, II vs. III, IV) 1.310 (0.297–5.777) 0.722
Chemotherapy (no vs. yes) 0.419 (0.160–1.100) 0.077
Radiation therapy (no vs. yes) 0.643 (0.177–2.337) 0.502
Surgery (no vs. yes) 0.983 (0.398–2.430) 0.971
Molecular targeted therapy (no vs. yes) 0.671 (0.123–3.659) 0.645
Physiotherapy (no vs. yes) 0.594 (0.044–7.968) 0.694
Interventional treatment (no vs. yes) 0.615 (0.174–2.171) 0.450
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DC-CTL/CIK treatment). Notably, the percentage of 
Treg cells in peripheral blood significantly decreased 
post-treatment (p < 0.05) in all tumor types (Fig. 3). This 
was a very encouraging observation, considering Treg 
as an immunosuppressive cell could induced immune 
escape and suppressed anti-tumor immune response. 
We also found that the proportion of CD3+  CD4+  T 
cells decreased significantly in colon cancer, primary 
liver cancer and lung cancer (p  <  0.05), while the per-
centage of CD3+ CD8+ T cells increased significantly in 
Fig. 1 Analysis of the percentage of cell markers. a The histogram showed the percentage of each marker. The X axis represented cell markers of 
CD80, CD83 CD86 CD11c, CD3+ CD8+ and CD3+ CD56+ respectively, and the proportion of positive cells was calculated that was represented on 
Y axis [cell counts (%)]. The standard deviation was also labeled on the histogram. b On Day 8, DCs were harvested and processed for staining with 
CD80+, CD83+, CD86+ and CD11c antibody respectively. The surface marker was identified by flow cytometry and the percentage of positive cells 
was stated. The first plot represented Isotype group
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primary liver cancer and lung cancer (p < 0.05). Among 
the 6 common tumor markers, the serum levels of AFP, 
CA19-9 and CA242 post-treatment were significantly 
lower than that of pre-therapy in primary liver cancer 
(p  <  0.05). The serum levels of CA724 also decreased 
significantly, which is often used in the diagnosis of gas-
tric cancer (p < 0.05). Additionally, there were 8 and 13 
patients showed declined levels of CEA and CA125 in 
serum, respectively, in which 4 and 8 patients returned 
to normal levels post-treatment, but the difference was 
not statistically significant (p > 0.05) (Additional files 1, 2: 
Figures S1, S2).
Systematic analysis of correlation between proportions 
of Tregs and prognosis
Subsequently, a  systematic analysis was performed to 
explore the changes of proportions of Tregs on the basis 
of treatment courses and therapeutic strategies. Notably, 
it demonstrated that long-lasting course treated patients 
(>3 times) had lower percentages of Tregs (5.65 ± 3.80 %) 
than  patients who only received  short-term therapy 
(6.07 ±  2.91  %), and proportion of Tregs reduced more 
significantly in patients with long-lasting course treat-
ment (p  =  0.0009) than those with short-term therapy 
(p  =  0.01) (Fig.  4a). Moreover, Treg indicator was also 
observed in patients with immunotherapy alone or in 
combination with adjuvant therapies, indicating that 
the percentage of Treg decreased for these patients with 
immunotherapy alone (6.77 ± 4.04 %) or combined with 
other adjuvant therapeutic strategies (5.3  ±  2.58  %), 
and it significantly decreased after combination of DC-
CTL/CIK therapy and adjuvant therapeutic strategies 
(p = 0.00005) (Fig. 4b). Then, the Cox’s proportional haz-
ards regression was further performed between patients 
with low (response) and high (non-response) proportions 
of Tregs. The  hazard  ratio was 2.021, indicating  higher 
hazard of death in non-response group.
Additionally, a heat map was  performed  to describe 
by  each six indicators of cancer to compare  the differ-
ence between different  types of  cancer pre-therapy. As 
shown in Fig.  4c, in fact, it is difficult to find a single 
marker that has high sensitivity and specificity to achieve 
Fig. 2 Detection of CIKs, CTLs and intracellular IFN-γ in T cells by flow cytometry. a On Day 10, the proportions of CD3+ CD56+ T cells were used 
to detect cytokine-induced killer cells (CIKs). And on Day 12, the proportion of CD3+ CD8+ T cells was used to identify cytotoxic T-lymphocyte 
cells (CTLs). The position of the gate was set by Isotype control. b The dot plots showed the proportion of T cells expressing IFN-γ. The left plot 
represented isotype control group, the middle plot represented Ad-Blank group, and the right plot represented the production of cytokines by DC 
induced antigen-specific CTL cells, and DC cells were infected by the recombinant non-proliferative adenovirus carrying the expression cassettes of 
TAAs
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clinical utility. An  elevated level  of a tumor  marker is 
different in many kinds of tumors. In our study, cases 
in Cohort 1 were positive for one of six tumor markers, 
the percentage of Treg cells significantly decreased post-
treatment in patients with all types of tumors. Thus, we 
further observed other 14 cases in Cohort 2 that were 
negative  for all  six  tumor markers pre-therapy. Interest-
ingly, the changes of immune indicators (Fig.  4d) were 
basically consistent with those of tumor marker posi-
tive cases, showing that the percentage of CD3+ CD8+ 
T cells increased and Tregs reduced significantly post-
treatment. Thus, we demonstrated that the percentage of 
Tregs was significantly correlated with the survival time 
of tumor patients and a combination of serological tumor 
markers and Treg to investigate the therapeutic roles of 
DC-CTL/CIK therapy could be more efficiently in the 
patients with malignant tumors.
Assessment of quality of life (QoL)
We measured quality of life of patients undergoing 
DC-CIK/CTL treatment. The QLQ-C30 has been sug-
gested to have multi-item subscales measuring function 
and symptom. A quality-of-life feature, QoL score, was 
designed to evaluate the balance between side effects 
and quality of life. It is inspiring that the QoL score of 25 
(41.7 %) patients improved obviously post treatment, and 
12 (20 %) patients did not take a turn for the worse. Thus, 
it indicated that DC-CIK/CTL therapy could at least 
partially block the deterioration of cancers in the patients 
with malignant tumors with elevated quality of life.
Comparison of MDSC levels pre‑ and post‑treatment 
of DC‑CTL/CIK therapy
To analyze the changes of MDSCs in DC-CTL/CIK ther-
apy, other nine patients were included for the detection 
of MDSCs and Tregs. The results showed a significant 
decrease in the proportion of MDSC and Treg after treat-
ment (p =  0.000681, p =  0.035, Fig. 5), which provided 
an additional proof of therapeutic effect of DC-CTL/
CIK therapy. Further studies  will be  needed  to confirm 
this preliminary result in our future work.
Side effects
The side-effects were also recorded in all cases. There 
were no severe or unusual side-effects recorded that 
are common in chemotherapy and radiotherapy during 
or after  the  transfusion, except for temporary fever. In 
total, 40 % patients developed a fever during the immu-
notherapy, and the body temperature was 37.5–38. These 
patients recovered without any treatment. Six out of 60 
(10 %) cases had temperatures >38 °C treated with drugs 
to lower body temperature.
Discussion
In this study, we collected three cohorts of patients to 
investigate therapeutic effect and immune modulation 
Fig. 3 Changes of immune indicators pre- and post-treatment in five types of tumors. The changes of CD3+, CD3+ CD4+, CD3+ CD8+, CD3+ 
CD56+ and Treg in patients with cholangiocarcinoma, colon cancer, primary liver cancer, gastric cancer and lung cancer pre-therapy and post-
treatment, respectively. *Statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001)
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Fig. 4 Analysis of correlation between proportions of Tregs and prognosis. a The changes of percentages of Treg cells in patients with short or 
long-term courses of immunotherapy, compared to pre-therapy group. The dot-bar represented patients enrolled in immunotherapy more than 
three cycles. b The changes of percentages of Treg cells in patients with immunotherapy alone or in combination with other adjuvant therapeutic 
strategies, compared to pre-therapy group. The diagonal-bar represented patients recruited during our immunotherapy combined with other adju-
vant therapies. *Statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001). c The heatmap showed the clinical values of 
six serum tumor markers for each type of tumor. Each color represented the level of tumor markers in serum, and the color legend was shown at the 
bottom of the heatmap. d The changes of immune indicators including CD3+, CD3+ CD4+, CD3+ CD8+, CD3+ CD56+ and Treg in 14 patients 
who were with negative for all serological indexes. *Statistically significant differences (*p < 0.05)
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of DC-CTL/CIK cells in malignant tumors both  at 
an  individual level  (changes of immune indicators and 
serological tumor markers pre- and post-treatment) 
and at a  system level  (correlation between proportions 
of Tregs and prognosis). We detected several serologi-
cal tumor markers and immune indicators pre-therapy. 
Levels of 6  common  tumor  markers in 60 cases were 
highly expressed in serum. The abnormal level of T lym-
phocyte subpopulations indicated severe damage of 
immune systems in these patients, and the accumulation 
of Tregs within the tumor microenvironment represents 
a major obstacle for the development of effective anti-
tumor immune-therapies [16, 20]. Excitingly, we found 
out that our DC-CTL/CIK therapy significantly reduced 
several serological tumor markers such as AFP, CA199 
and CA242 in primary liver cancer and CA724 in gastric 
cancer (p  <  0.05), elevated the level of CD3+ CD8+ T 
cells in primary liver cancer and lung cancer (p < 0.05), 
and decreased the level of CD3+ CD4+ T cells in colon 
cancer, primary liver cancer and lung cancer (p  <  0.05) 
and Treg cells in all types of tumors (p  <  0.05), which 
indicated the promotion of immune functions in these 
patients. The quality of life (QoL score) of patients was 
improved after treatment which could be indicate that 
it exerts immune and clinical responses in patients with 
malignant tumors DC/CIK treatment.
A systematic analysis was performed to discuss the cor-
relation between proportions of Tregs and prognosis, and 
whether a combination of immune indicators especially 
Treg indicator with serum tumor markers could be a 
better way to evaluate therapy responses. Tregs within 
tumors represented a major obstacle for cancer immuno-
therapy [21, 22]. In previous studies, it has been reported 
that Tregs decreased the cytotoxicity of CIK cells, and 
the down-regulation of Tregs could strengthen the kill-
ing activity of CIK cells to tumor cells [14, 16, 23]. Tao 
[16] and Lin [23] indicated that the addition of IL-6, 
IL-7, IL-15 during CIK cell culture in  vitro inhibited 
the production of Tregs. Pan [14] suggested that DC 
cells decreased concomitant expanded Tregs and Tregs 
related IL-35 in CIK cells, to against leukemia cell lines 
K562 and NB4.
Here, compared with the prior methods, we also pro-
vided a novel cell culture program in the yield of DC 
cells, a cocktail of antigens and incubation time, to sig-
nificantly reduce the proportion of Tregs. As in our cell 
culture protocol, it has greatly reduced the percentage of 
Tregs (less than 7 %). Analysis at a system level showed 
that long-lasting course of DC/CIK treated patients (>3 
cycles) had lower percentages of Tregs than patients who 
only received  short-term therapy, and the percentage 
of Treg  was  lower  for  these patients with immunother-
apy alone or combined with other adjuvant therapeutic 
strategies.
Moreover, to date, the detection of  tumor markers 
has been widely used in cancer screening, early diag-
nosis, monitoring efficacy  of treatment, and prognostic 
evaluation [24–27]. In fact, it is difficult to find a single 
Fig. 5 Significance of MDSC populations in peripheral blood. a The changes of MDSC levels pre- and post-treatment of DC-CTL/CIK therapy in each 
nine patient (cohort 3). b The histogram showed the percentage of Treg cells and MDSC cells in cohort three patients pre-therapy and post-treat-
ment. *Statistically significant differences (*p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001)
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marker that has high sensitivity and specificity to indi-
cate a cancer. For instance, alpha-fetoprotein (AFP), 
a  widely  accepted  biomarker  of hepatocellular carcino-
mas (HCC), in some patients with advanced HCC may 
still be negative. AFP in our dataset was elevated in 94 % 
of  liver cancer patients, but 10 cases were AFP-negative. 
As such, it is likely that the effect of DC-CTL/CIK immu-
notherapy would not be suitably assessed by methods 
based on response evaluation criteria in solid tumors 
(RECST). Therefore, it is  urgently  necessary  to  iden-
tify and validate reliable biomarkers to evaluate clinical 
responses and outcomes of immunotherapy including 
DC-CTL/CIK therapy. A methodology named “Immu-
noscore”, which numerates lymphocytes both in tumor 
center (CT) and invasive margin (IM), has been intro-
duced to add to the significance of the American Joint 
Committee on Cancer (AJCC)-Union for International 
Cancer Control (UICC)-Tumor Node Metastasis (TNM)-
classification, and to establish prognosis of clinical out-
come in patients [28]. In our study, we proposed that 
altered  immune  phenotype  in  peripheral  blood  cells of 
patients may have clinical value in the evaluation of thera-
peutic effects and clinical outcome, especially Treg cell as 
a potent immunosuppressive cell which promote tumor 
growth and invasion. MDSC also has been proposed to 
have contribution to immune-suppression, and have asso-
ciation with grades, stages, tumor burden and clinical 
outcomes in patients with different types of cancer [29]. 
MDSCs can influence the proliferation and activation of 
T cells, NK cells, dendritic cells and macrophages, espe-
cially in inhibiting CD8+ T cell responses [30–32]. Diaz-
Montero [33] demonstrated that MDSC can be referred 
to as an independent prognostic indicator by multivari-
ate Cox proportional hazards analysis. Here, we also per-
form a preliminary investigation of MDSCs in peripheral 
blood pre and post-therapy, and more verification experi-
ments are needed to undertake this improvement in the 
future.
In addition, as many papers have published that neo-
antigens in cancer immunotherapy and personalized anti-
gen for the treatment [34], optimization of this program 
will be further performed to standardize and facilitate 
the  cell  culture  process. Besides DC-CTL/CIK immuno-
therapy in this study, other immunotherapeutic agents 
also have made great progress in clinic, such as immune 
checkpoint inhibitor antibodies of PD-1/PD-L1 or CTLA-
4, and chimeric antigen receptor-T cell (CAR-T) target-
ing specific tumor antigen. CTLA-4 antibody ipilimumab, 
PD-1 antibody pembrolizumab and nivolumab have been 
approved by FDA [35]. The most successfully application 
of CAR-T is on chronic lymphocytic leukemia patients, 
which specifically binds to CD19 marker. However, immu-
nosuppressive microenvironment in tumor (surrounding 
with Treg, MDSC, etc.) may greatly impaired the thera-
peutic effects of immune checkpoint inhibitors and CAR-
T. Moreover, there are rare target antigens for T cell 
engineering [10, 36]. Our DC-CTL/CIK immunothera-
peutic agents can greatly improve the system of immune 
function and reduce Tregs and MDSCs in peripheral 
blood, and also with widely antitumor spectrum of solid 
tumors. Furthermore, combination of DC-CTL/CIK with 
immune checkpoint inhibitors or CAR-T may bring out 
better clinical result, and the clinical trials are being under-
taken in our hospital which is believed to greatly improve 
the therapeutic effect of immunotherapy in the future.
In summary, our results demonstrated that DC-CTL/
CIK therapy as an immunotherapeutic regimen could 
influence the immune status, and patients  with  late-
stage malignant tumor may benefit from this therapeutics. 
Our data conclusively exhibited immune improvement 
by impairing the immune-suppressive Tregs after DC-
CTL/CIK therapy. This immune response is continuously 
modulated with the increasing of treatment courses. We 
have also showed a combination of DC-CTL/CIK therapy 
with other adjuvant therapeutic strategies could reduce 
the percentages of Treg significantly, and a decrease 
frequency and depleted suppressive activity of Tregs in 
peripheral blood in patients which have a strong correla-
tion  with prognosis. Thus, this work may provide valu-
able insights into the clinical curative effect evaluation of 
DC-CTL/CIK therapy and the design of immunothera-
peutic strategies for malignant tumors.
Abbreviations
DC: dendritic cells; CIK: cytokine-induced killer; CTL: cytotoxic T lymphocytes; 
MDSC: myeloid-derived suppressor cells; PBMCs: peripheral blood mono-
nuclear cells; EORTC: European Organization for Research and Treatment 
of Cancer; QoL: quality of life; AFP: Alpha-fetoprotein; HCC: hepatocellular 
carcinomas; CT: tumor center; IM: invasive margin; AJCC: American Joint Com-
mittee on Cancer; UICC: Union for International Cancer Control; TNM: tumor 
node metastasis.
Authors’ contributions
YW and ZX designed the pipeline of the analysis, and drafted the manuscript. 
YW detected the immune indicator and performed the statistical analysis. 
FZ collected clinical data. YS, JC and LL cultured DC, CIK and CTL cells for 
immunotherapy. HJ revised the manuscript. QQ conceived and coordinated 
Additional files
Additional file 1: Figure S1. Changes of serum level of AFP and CEA 
pre- and post-treatment in five types of tumors. Analysis of the changes of 
AFP and CEA in patients with cholangiocarcinoma, colon cancer, primary 
liver cancer, gastric cancer and lung cancer pre-therapy and post-treat-
ment, respectively. *Statistically significant differences (*p < 0.05).
Additional file 2: Figure S2. Changes of serum level of tumor marker 
carbohydrate antigen pre- and post-treatment in five types of tumors. 
Analysis of the changes of CA199, CA724, CA125 and CA242 in patients 
with cholangiocarcinoma, colon cancer, primary liver cancer, gastric 
cancer and lung cancer pre-therapy and post-treatment, respectively. 
*Statistically significant differences (*p < 0.05).
Page 11 of 12Wang et al. Exp Hematol Oncol  (2015) 4:32 
the overall study and revised the manuscript. All authors read and approved 
the final manuscript.
Author details
1 Laboratory of Gene and Viral Therapy, Eastern Hepatobiliary Surgery Hospital, 
the Second Military Medical University of Chinese PLA, Shanghai 200438, 
China. 2 Department of Biotherapy, Eastern Hepatobiliary Surgery Hospital, the 
Second Military Medical University of Chinese PLA, Shanghai 200438, China. 
Acknowledgements
This study was funded by the National Natural Science Founda-
tion of China (Grant Number 81301307) and the National Science and Tech-
nology Major Project (Grant Number 2013ZX10002-010-007).
Competing interests
The authors declare that they have no competing interests.
Received: 3 July 2015   Accepted: 30 October 2015
References
 1. Chen R, Deng X, Wu H, Peng P, Wen B, Li F, Li F. Combined immunother-
apy with dendritic cells and cytokine-induced killer cells for malignant 
tumors: a systematic review and meta-analysis. Int Immunopharmacol. 
2014;22:451–64.
 2. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, Sabaawy 
HE, Abdelhalim O. Immunotherapy by autologous dendritic cell vaccine 
in patients with advanced HCC. J Cancer Res Clin Oncol. 2013;139:39–48.
 3. Hontscha C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials 
on CIK cells: first report of the international registry on CIK cells (IRCC). J 
Cancer Res Clin Oncol. 2011;137:305–10.
 4. Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS. 
Autologous cytokine-induced killer cell therapy in clinical trial phase I is 
safe in patients with primary hepatocellular carcinoma. World J Gastroen-
terol. 2004;10:1146–51.
 5. Jakel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IG. Clinical studies 
applying cytokine-induced killer cells for the treatment of gastrointestinal 
tumors. J Immunol Res. 2014;2014:897214.
 6. Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang C, Zhang J, Li J, Pang Y. Immune 
response, safety, and survival and quality of life outcomes for advanced 
colorectal cancer patients treated with dendritic cell vaccine and 
cytokine-induced killer cell therapy. Biomed Res Int. 2014;2014:603871.
 7. Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical 
outcome and safety of dendritic cell vaccine in combination with 
cytokine-induced killer cell therapy in cancer patients. Oncol Lett. 
2013;6:537–41.
 8. Ma Y, Xu YC, Tang L, Zhang Z, Wang J, Wang HX. Cytokine-induced killer 
(CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and 
safety. Exp Hematol Oncol. 2012;1:11.
 9. Li XD, Xu B, Wu J, Ji M, Xu BH, Jiang JT, Wu CP. Review of Chinese 
clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol. 
2012;14(2):102–8.
 10. Shi L, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune 
suppression in patients with hematological malignancies. J Hematol 
Oncol. 2013;6:74.
 11. Wang XP, Xu M, Gao HF, Zhao JF, Xu KC. Intraperitoneal perfusion of 
cytokine-induced killer cells with local hyperthermia for advanced hepa-
tocellular carcinoma. World J Gastroenterol. 2013;19(19):2956–62.
 12. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, Xu B, Wu J, Wang R, Xu J, 
Nilsson-Ehle P. Treatment of advanced gastric cancer by chemotherapy 
combined with autologous cytokine-induced killer cells. Anticancer Res. 
2006;26:2237–42.
 13. Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regi-
men combined with a dendritic cell-cytokine induced killer immuno-
therapy on recurrence and survival rate of non-small cell lung cancer 
patients. Exp Ther Med. 2014;7(5):1403–7.
 14. Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, Tao L, Zhai Z. Dendritic 
cells decreased the concomitant expanded Tregs and Tregs related IL-35 
in cytokine-induced killer cells and increased their cytotoxicity against 
leukemia cells. PLoS One. 2014;9:e93591.
 15. Qu HQ, Zhou XS, Zhou XL, Wang J. Effect of DC-CIK cell on the prolifera-
tion, apoptosis and differentiation of leukemia cells. Asian Pac J Trop Med. 
2014;7:659–62.
 16. Tao Q, Wang H, Zhai Z. Targeting regulatory T cells in cytokine-induced 
killer cell cultures (Review). Biomed Rep. 2014;2(3) :317–20.
 17. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-
derived suppressor cell heterogeneity in human cancers. Ann N Y Acad 
Sci. 2014;1319:47–65.
 18. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, Duric VM, Jensen PT, 
Singer S, Chie W, Nordin A, Bjelic Radisic V, Wydra D. The European 
Organization for Research and Treatment of Cancer (EORTC) quality-of-
Life questionnaire cervical cancer module: EORTC QLQ-CX24. Cancer. 
2006; 107:1812–22.
 19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, 
Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a quality-
of-life instrument for use in international clinical trials in oncology. J Natl 
Cancer Inst. 1993;85:365–76.
 20. Li H, Yu JP, Cao S, Wei F, Zhang P, An XM, Huang ZT, Ren XB. CD4 
+CD25 + regulatory T cells decreased the antitumor activity of 
cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol. 
2007;27:317–26.
 21. Heeren AM, Koster BD, Samuels S, Ferns DM, Chondronasiou D, Kenter 
GG, Jordanova ES, de Gruijl TD. High and interrelated rates of PD-L1+ 
CD14+ antigen-presenting cells and regulatory T cells mark the microen-
vironment of metastatic lymph nodes from patients with cervical cancer. 
Cancer Immunol Res. 2015;3(1):48–58.
 22. Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Mur-
phy WJ, Wiltrout RH. Regulatory T Cells and myeloid-derived suppressor 
cells in the tumor microenvironment undergo fas-dependent cell death 
during IL-2/alphaCD40 therapy. J Immunol. 2014;192(12):5821–9.
 23. Lin G, Wang J, Lao X, Li L, Li S, Zhang J, Dong Y, Chang AE, Li Q. 
Interleukin-6 inhibits regulatory T cells and improves the proliferation 
and cytotoxic activity of cytokine-induced killer cells. J Immunother. 
2012;35:337–43.
 24. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol 
Clin Oncol. 2013;1(4):593–8.
 25. Sawabu N, Watanabe H, Yamaguchi Y, Ohtsubo K, Motoo Y. Serum tumor 
markers and molecular biological diagnosis in pancreatic cancer. Pan-
creas. 2004;28:263–7.
 26. Kurebayashi J, Nishimura R, Tanaka K, Kohno N, Kurosumi M, Moriya T, 
Ogawa Y, Taguchi T. Significance of serum tumor markers in monitor-
ing advanced breast cancer patients treated with systemic therapy: a 
prospective study. Breast Cancer. 2004;11:389–95.
 27. Sigari N, Mohsenpour B, Nikkhoo B, Ghaderi B, Afkhamzadeh A, Azadi 
NA, Fathi F, Abdi M. Determination of the best prognostic value of serum 
tumor markers in patients with suspected lung cancer in an Iranian 
population. Clin Lab. 2014;60(1):23–7.
 28. Angell H, Galon J. From the immune contexture to the Immunoscore: the 
role of prognostic and predictive immune markers in cancer. Curr Opin 
Immunol. 2013;25:261–7.
 29. Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo 
AM, Maio M, Sucker A, Schilling B, Schadendorf D, et al. Myeloid-derived 
suppressor cells predict survival of patients with advanced melanoma: 
comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T 
cells. Clin Cancer Res. 2014;20(6):1601–9.
 30. Jitschin R, Braun M, Buttner M, Dettmer-Wilde K, Bricks J, Berger J, Eckart 
MJ, Krause SW, Oefner PJ, Le Blanc K, et al. CLL-cells induce IDOhi CD14+ 
HLA-DRlo myeloid derived suppressor cells that inhibit T-cell responses 
and promote TRegs. Blood. 2014;124(5):750–60.
 31. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators 
of the immune system. Nat Rev Immunol. 2009;9:162–74.
 32. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mecha-
nisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 
2010;59(10):1593–1600.
Page 12 of 12Wang et al. Exp Hematol Oncol  (2015) 4:32 
 33. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, 
Montero AJ. Increased circulating myeloid-derived suppressor cells corre-
late with clinical cancer stage, metastatic tumor burden, and doxoru-
bicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 
2009;58:49–59.
 34. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. 
Science. 2015;348:69–74.
 35. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 
2015;348:56–61.
 36. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engi-
neered T cells for cancer immunotherapy: progress and challenges. J 
Hematol Oncol. 2013;6:47.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
